BridgeBio Oncology Therapeutics, Inc. (BBOT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BridgeBio Oncology Therapeutics, Inc. (BBOT) has a cash flow conversion efficiency ratio of -0.096x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-35.92 Million) by net assets ($372.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BridgeBio Oncology Therapeutics, Inc. balance sheet quality to measure how much of total assets are equity-financed.
BridgeBio Oncology Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how BridgeBio Oncology Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of BridgeBio Oncology Therapeutics, Inc. to evaluate the quality of earnings relative to operating cash generation.
BridgeBio Oncology Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BridgeBio Oncology Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang JW Precision Machinery Co.Ltd
SHE:300984
|
0.004x |
|
DCB Bank Limited
NSE:DCBBANK
|
-0.040x |
|
Corporación Actinver S. A. B. de C. V
MX:ACTINVRB
|
-1.531x |
|
Jiahe Foods Industry Co. Ltd.
SHG:605300
|
0.014x |
|
Sichuan Huiyu Pharmaceutical Co Ltd
SHG:688553
|
0.016x |
|
Lindian Resources Ltd
AU:LIN
|
-0.046x |
|
Qian Jiang Water Resources Development Co Ltd
SHG:600283
|
0.032x |
|
Shanghai Laiyifen Co Ltd
SHG:603777
|
0.040x |
Annual Cash Flow Conversion Efficiency for BridgeBio Oncology Therapeutics, Inc. (2023–2025)
The table below shows the annual cash flow conversion efficiency of BridgeBio Oncology Therapeutics, Inc. from 2023 to 2025. For the full company profile with market capitalisation and key ratios, see BridgeBio Oncology Therapeutics, Inc. (BBOT) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $411.10 Million | $-113.89 Million | -0.277x | -6745.05% |
| 2024-12-31 | $188.72 Million | $-763.82K | -0.004x | -100.00% |
| 2023-12-31 | $-63.57K | $-52.08 Million | 819.252x | -- |
About BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients… Read more